Natural history of hepatitis B virus-related cirrhotic patients hospitalized to control ascites

J Gastroenterol Hepatol. 2008 Nov;23(11):1722-7. doi: 10.1111/j.1440-1746.2008.05510.x. Epub 2008 Aug 20.

Abstract

Background and aim: Few studies have assessed the natural history of hepatitis B virus (HBV)-related cirrhotic ascites. We investigated the natural history of patients with HBV-related cirrhotic ascites hospitalized to control ascites and determined their prognosis, including survival rates and prognostic factors affecting survival.

Methods: Between January 1996 and December 2005, 203 consecutive patients with HBV-related cirrhotic ascites were followed for a median of 80.7 months (range, 15-149) after their first significant ascitic decompensation that required hospitalization.

Results: The mean age of all patients was 52.6 years. Male gender predominated (male/female, 138/65). A subgroup analysis of 165 patients who had ascitic decompensation as their first episode of hepatic decompensation revealed that gastrointestinal variceal bleeding developed after a median interval of 8 months following ascitic decompensation in 31 (18.8%) patients, hepatic encephalopathy occurred at 9 months in 53 (32.1%), spontaneous bacterial peritonitis appeared at 12.7 months in 24 (14.5%), hepatorenal syndrome occurred at 8.1 months in five (3%), and hepatocellular carcinoma was observed at 21.2 months in 10 (6.1%). The overall median survival was 12.4 months. The 1- and 3-year survival rates were 50.7 and 18.7%. The prognostic factors that independently correlated with survival at the time of ascitic decompensation were Child-Pugh classification B/C (P = 0.030), serum white blood cell (WBC; P = 0.035), serum creatinine (Cr; P = 0.039), serum sodium (Na; P = 0.010), and antiviral therapy (P = 0.040).

Conclusions: The prognosis of HBV-related cirrhotic patients with ascitic decompensation is poor. Child-Pugh class, serum WBC/Cr/Na, and antiviral therapy primarily influenced survival.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antiviral Agents / therapeutic use
  • Ascites / mortality
  • Ascites / therapy
  • Ascites / virology*
  • Carcinoma, Hepatocellular / virology
  • Creatinine / blood
  • Disease Progression
  • Esophageal and Gastric Varices / virology
  • Female
  • Gastrointestinal Hemorrhage / virology
  • Hepatic Encephalopathy / virology
  • Hepatitis B / complications*
  • Hepatitis B / mortality
  • Hepatitis B / therapy
  • Hepatorenal Syndrome / virology
  • Hospitalization*
  • Humans
  • Kaplan-Meier Estimate
  • Leukocyte Count
  • Liver Cirrhosis / complications
  • Liver Cirrhosis / mortality
  • Liver Cirrhosis / therapy
  • Liver Cirrhosis / virology*
  • Liver Neoplasms / virology
  • Male
  • Middle Aged
  • Peritonitis / microbiology
  • Peritonitis / virology
  • Prognosis
  • Proportional Hazards Models
  • Retrospective Studies
  • Risk Assessment
  • Risk Factors
  • Severity of Illness Index
  • Sodium / blood
  • Time Factors

Substances

  • Antiviral Agents
  • Sodium
  • Creatinine